0.2776
price down icon5.58%   -0.0164
pre-market  시장 영업 전:  .27   -0.0076   -2.74%
loading

Theriva Biologics Inc 주식(TOVX)의 최신 뉴스

pulisher
Jun 12, 2026

TOVX Should I Buy - Intellectia AI

Jun 12, 2026
pulisher
Jun 11, 2026

Why is Theriva stock gaining Monday? - MSN

Jun 11, 2026
pulisher
Jun 11, 2026

Theriva Biologics (TOVX) Surges Over 26%: Key Levels to Watch After BreakoutCall Resistance - newsline.com

Jun 11, 2026
pulisher
Jun 11, 2026

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention - TechStock²

Jun 11, 2026
pulisher
Jun 11, 2026

Theriva Biologics reports survival data from VCN-01 cancer trial - Investing.com

Jun 11, 2026
pulisher
Jun 11, 2026

Theriva Biologics highlights promising VCN-01 Phase 1 results - TipRanks

Jun 11, 2026
pulisher
Jun 11, 2026

$Theriva Biologics (TOVX.US)$ - Moomoo

Jun 11, 2026
pulisher
Jun 11, 2026

Theriva Biologics (NYSE American: TOVX) shares VCN-01 Phase 1 head and neck cancer data - Stock Titan

Jun 11, 2026
pulisher
Jun 11, 2026

Small trial: virus-immunotherapy combo linked to longer survival in head and neck cancer - Stock Titan

Jun 11, 2026
pulisher
Jun 07, 2026

TOVX Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesOperating Margin Analysis - newsline.com

Jun 07, 2026
pulisher
Jun 05, 2026

Theriva Biologics Faces Quorum Issue Delaying Warrant Vote - TipRanks

Jun 05, 2026
pulisher
Jun 05, 2026

Theriva Biologics (NYSE: TOVX) fails quorum, delays 16.18M-warrant share vote - Stock Titan

Jun 05, 2026
pulisher
May 31, 2026

MSN Money - MSN

May 31, 2026
pulisher
May 31, 2026

Number of shareholders of Theriva Biologics, Inc. – AMEX:TOVX - TradingView

May 31, 2026
pulisher
May 29, 2026

Theriva Biologics (TOVX) Slides 8% as Stock Tests Key Support at $0.27Dark Pool Sentiment - The Legal Advocate

May 29, 2026
pulisher
May 29, 2026

Theriva Biologics (TOVX) Faces Pressure: Stock Slides 8% as Key Support Levels Are TestedLeveraged ETF Flow - The Legal Advocate

May 29, 2026
pulisher
May 29, 2026

Theriva Biologics (TOVX) Slides 6.15% as Stock Approaches Key Support at $0.28Thematic ETF Flow - newsline.com

May 29, 2026
pulisher
May 28, 2026

Theriva Biologics (TOVX) Advances 4.99% as Stock Approaches Key Resistance at $0.33McClellan Oscillator - newsline.com

May 28, 2026
pulisher
May 28, 2026

Theriva Biologics (TOVX) Gains Nearly 5% as Stock Attempts to Recover Key Support LevelsAI Trade Signals - The Legal Advocate

May 28, 2026
pulisher
May 26, 2026

Theriva Biologics (TOVX) Slides 5.73% as Price Nears Critical Support at $0.28BPI Reversal - The Legal Advocate

May 26, 2026
pulisher
May 24, 2026

Theriva Biologics (TOVX) Q1 2026 Earnings: Slight EPS Beat Boosts Sentiment for Clinical-Stage BiotechMargin Guidance - The Legal Advocate

May 24, 2026
pulisher
May 22, 2026

Theriva Biologics (TOVX) Q1 2026 Earnings: Narrowed Loss Beats Expectations as Stock RisesBanking Earnings Report - Newser

May 22, 2026
pulisher
May 21, 2026

Theriva Biologics (TOVX) Dips 1% as Stock Hovers Near Key Support at $0.28Value Area Low - Newser

May 21, 2026
pulisher
May 21, 2026

Theriva Biologics (TOVX) Hovers Near Support After Modest DeclineCommunity Breakout Alerts - Newser

May 21, 2026
pulisher
May 19, 2026

Theriva Biologics (TOVX) Delivers Q1 2026 Beat — EPS $-0.05 vs $-0.05 ExpectedShared Trade Ideas - Newser

May 19, 2026
pulisher
May 17, 2026

Theriva Biologics (TOVX) Declines -9.35% Amid Market Weakness 2026-05-17Top Analyst Buy Signals - Newser

May 17, 2026
pulisher
May 15, 2026

Theriva Biologics (TOVX) Falls -11.84% — Watching $0.27 Support 2026-05-15Diversification - Newser

May 15, 2026
pulisher
May 12, 2026

BIOLASE Inc (BIOL) - Minichart

May 12, 2026
pulisher
May 11, 2026

TradingKey - TradingKey

May 11, 2026
pulisher
May 08, 2026

TOVX SEC FilingsTHERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan

May 08, 2026
pulisher
May 07, 2026

Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo

May 07, 2026
pulisher
May 06, 2026

Theriva Biologics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and Key Disclosures - Minichart

May 06, 2026
pulisher
May 05, 2026

Theriva Biologics Reports FDA Alignment on VCN-01 Phase 3 Trial Design for Metastatic Pancreatic Cancer and Q1 2026 Financial Results - Minichart

May 05, 2026
pulisher
May 05, 2026

Theriva Biologics, Inc. 1Q 2026: Revenue $300K, Net income ($2.04M), EPS ($0.05) — 10-Q Summary - TradingView

May 05, 2026
pulisher
May 05, 2026

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - The Manila Times

May 05, 2026
pulisher
May 05, 2026

Theriva Biologics: Q1 Earnings Snapshot - marketscreener.com

May 05, 2026
pulisher
May 05, 2026

Theriva Biologics (NYSE American: TOVX) posts Q1 loss, flags going concern risk - Stock Titan

May 05, 2026
pulisher
May 05, 2026

Theriva Biologics (NYSE: TOVX) narrows Q1 loss and advances VCN-01 toward pivotal trials - Stock Titan

May 05, 2026
pulisher
May 05, 2026

Theriva moves pancreatic cancer drug toward Phase 3, cash into 2027 - Stock Titan

May 05, 2026
pulisher
May 01, 2026

TOVX Forecast, Price Target & Analyst Ratings | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill

May 01, 2026
pulisher
Apr 30, 2026

Warrant vote could unlock $8.7M for Theriva Biologics (TOVX) - Stock Titan

Apr 30, 2026
pulisher
Apr 28, 2026

TOVX|Theriva Biologics Inc|Price:0.330|Chg%:-0.03 - TradingKey

Apr 28, 2026
pulisher
Apr 26, 2026

Theriva Biologics (TOVX) price target decreased by 42.86% to 4.08 - MSN

Apr 26, 2026
pulisher
Apr 26, 2026

Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo

Apr 26, 2026
$30.41
price up icon 1.27%
$55.40
price up icon 6.27%
$89.50
price down icon 1.43%
$54.21
price down icon 0.11%
ONC ONC
$263.92
price down icon 1.60%
$156.58
price down icon 2.17%
자본화:     |  볼륨(24시간):